High-Intensity Statin Administration Decreased 12-Month Major Adverse Cardiac Events In Asian Population: From Korean Acute Myocardial Infarction Registry-National Institute of Health
Background:
There have been conflicting results in reducing major adverse cardiac events (MACEs) by high-intensity statin in asian acute myocardial infarction (AMI) patients. The aim of our study was to investigate the clinical effects of high-intensity statin in Korean Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) patients during 12-month clinical follow-up.
Methods:
Between November 2011 and July 2015, a total of 10,567 patients [63.3±12.5 years, male 7,925 (75.0%)] were enrolled. Patients were divided into two groups (group I: high-intensity, n=3,627, group II: moderate-intensity, n=6,940 according to the intensity of statin used for secondary prevention. This research was supported by a fund (2013-E63005-02) by Research of Korea Centers for Disease Control and Prevention.
Results:
Though the incidence of cardiac death [group I vs group II, 61 (1.7%) vs 132 (1.9%), p=NS] was not different, all cause death [73 (2.0%) vs 211 (3.0%), p<0.05], and non-cardiac death [12 (0.3%) vs 79 (1.1%), p<0.05] was lower in group I during 6-month. The incidence of 12-month primary and secondary endpoints were lower in group II.
Conclusions:
The present study showed that high-intensity statin have clinical benefit by MACE reduction in asian patients. The long-term follow up would be needed to clarify our results.
| High-intensity statin (n=3,627) | moderate-intensity statin (n=6,940) | |
| All cause death*, n(%) | 111(3.1%) | 333(4.8%) |
| Cardiac death*, n(%) | 83(2.3%) | 206(3.0%) |
| Non-cardiac death*, n(%) | 28(0.8%) | 127(1.8%) |
| Myocardial infarction*, n(%) | 97(2.7%) | 259(3.7%) |
| Revascularization, n(%) | 192(5.3%) | 401(5.8%) |
| Re-PCI, n(%) | 185(5.1%) | 393(5.7%) |
| CABG, n(%) | 7(0.2%) | 8(0.1%) |
| Stroke*, n(%) | 91(2.5%) | 240(3.5%) |
| Stent thrombosis, n(%) | 8(0.2%) | 7(0.1%) |
| Primary endpoint*, n(%) | 235(6.5%) | 524(7.6%) |
| Primary endpoint: composite of 12-month MACEs including cardiac death, myocardial infarction, repeat revascularization, *p<0.05 | ||